scholarly journals Antiviral Medications for the Prevention of Postherpetic Neuralgia After Herpes Zoster Infection

2019 ◽  
Vol 26 (6) ◽  
pp. 684-685
Author(s):  
Daniel S. Kowalsky ◽  
Allan B. Wolfson
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Herpes Zoster Infection ◽  
Antiviral Medications

Postherpetic Neuralgia: A Patient’s and a Physician’s Perspective

2016 ◽  
Author(s):  
James H. Diaz
Keyword(s):  
Neuropathic Pain ◽  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Clinical Manifestations ◽  
The United States ◽  
Evidence Based ◽  
Pain Medicine ◽  
High Prevalence ◽  
Antiviral Medications ◽  
Physician’S Perspective

Herpes zoster can plague anyone who has had varicella or has received the varicella or chickenpox vaccine. The incidence of herpes zoster increases with age and rises exponentially after 60 years of age. Postherpetic neuralgia (PHN) may occur after herpes zoster at any age but typically occurs after 50 years of age, with over 40% of persons over 60 years of age suffering from PHN after a shingles attack. Up to 1 million new cases of herpes zoster and 200,000 new cases of PHN may now be anticipated in the United States every year, with the incidence rate increasing as the population grows and ages with prolonged life expectancies. Although new antiviral medications will improve and shorten the course of herpes zoster, they do not guarantee the prevention of PHN. Given the high prevalence of PHN in an aging population and the availability of primary prevention by vaccination, the objectives of this review are to describe the epidemiology, pathophysiology, and clinical manifestations of zoster and PHN and to recommend a combination of strategies for the clinical management and prevention of PHN. This review contains 6 figures, 4 tables and 13 references Key words: evidence-based pain medicine, herpes zoster, neuropathic pain, postherpetic neuralgia

scholarly journals Recurrent herpes zoster with segmental paresis and postherpetic neuralgia

2014 ◽  
Vol 71 (2) ◽  
pp. 214-217 ◽  
Author(s):  
Vesna Martic
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Complete Recovery ◽  
The Body ◽  
Chronic Lymphatic Leukemia ◽  
Virus Reactivation ◽  
Herpes Zoster Infection ◽  
Lymphatic Leukemia ◽  
Recurrent Herpes ◽  
Different Parts

Introduction. Postherpetic neuralgia and segmental paresis represent rare complications of herpes zoster infection. Recurrent herpes zoster is also rare and occurs within the first 3 years of the begining of the illness in only 1.4% of cases but it is generally higher in cases of chronic lymphatic leukemia (3.5%). Case report. We presented a patient with lymphatic leukemia who during the remission had 3 episodes of herpes zoster over a year. All of them took different parts of the body. One of these episodes was complicated by postherpetic neuralgia and segmental paresis. A complete recovery was seen in all the three episodes. Conclusion. As immunosuppression is one of mechanisms of virus reactivation, it is likely associated with the described rare complications of herpes zoster.

Effect of Cimetidine on Herpes Zoster Infection

1987 ◽  
Vol 21 (10) ◽  
pp. 803-805 ◽  
Author(s):  
László Bense ◽  
Jan A. Marcusson ◽  
Thomas Ramsten
Keyword(s):  
Herpes Zoster ◽  
Acute Pain ◽  
Postherpetic Neuralgia ◽  
Herpes Zoster Infection

Cimetidine was administered to two patients for herpes zoster infection. An acute pain-relieving effect was observed. The patients were followed for 11 and 14 months without developing postherpetic neuralgia. Possible mechanisms for prevention of postherpetic neuralgia by cimetidine are discussed.

scholarly journals Topical (S)-ketamine for pain management of postherpetic neuralgia

2012 ◽  
Vol 87 (3) ◽  
pp. 504-505 ◽  
Author(s):  
Guilherme Antonio Moreira de Barros ◽  
Hélio Amante Miot ◽  
Ademir Massarico Braz ◽  
Flávia Ramos ◽  
Marcos Aristoteles Borges
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Statistical Difference ◽  
Topical Administration ◽  
Herpes Zoster Infection ◽  
Pain Scores ◽  
Cutaneous Reactions ◽  
Prolonged Pain

Herpes zoster infection may cause postherpetic neuralgia, which is defined by prolonged pain predominantly mediated by central nervous system hypersensitivity. This phenomenon may be reversed by (S)-ketamine (SKET), but its use results in intolerable side effects, while its topical administration seems to be safe. It is a cross-over design study with 12 patients randomly divided into two groups. There was a significant effect of time on pain intensity, but no statistical difference in pain scores for SKET or placebo use in this sample in this treatment regimen. Only few mild cutaneous reactions were observed with topical SKET use.

scholarly journals Corticosteroids for Preventing Postherpetic Neuralgia After Herpes Zoster Infection

2019 ◽  
Vol 26 (6) ◽  
pp. 686-687
Author(s):  
Daniel S. Kowalsky ◽  
Allan B. Wolfson
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Herpes Zoster Infection

Postherpetic Neuralgia: A Patient’s and a Physician’s Perspective

2017 ◽  
Author(s):  
James H. Diaz
Keyword(s):  
United States ◽  
Neuropathic Pain ◽  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Clinical Manifestations ◽  
The United States ◽  
Evidence Based ◽  
Pain Medicine ◽  
High Prevalence ◽  
Antiviral Medications

Herpes zoster can plague anyone who has had varicella or has received the varicella or chickenpox vaccine. The incidence of herpes zoster increases with age and rises exponentially after 60 years of age. Postherpetic neuralgia (PHN) may occur after herpes zoster at any age but typically occurs after 50 years of age, with over 40% of persons over 60 years of age suffering from PHN after a shingles attack. Up to 1 million new cases of herpes zoster and 200,000 new cases of PHN may now be anticipated in the United States every year, with the incidence rate increasing as the population grows and ages with prolonged life expectancies. Although new antiviral medications will improve and shorten the course of herpes zoster, they do not guarantee the prevention of PHN. Given the high prevalence of PHN in an aging population and the availability of primary prevention by vaccination, the objectives of this review are to describe the epidemiology, pathophysiology, and clinical manifestations of zoster and PHN and to recommend a combination of strategies for the clinical management and prevention of PHN. Key words: evidence-based pain medicine, herpes zoster, neuropathic pain, postherpetic neuralgia

Effect of Ganoderma lucidum on Postherpetic Neuralgia

1998 ◽  
Vol 26 (03n04) ◽  
pp. 375-381 ◽  
Author(s):  
Yasuyo Hijikata ◽  
Seika Yamada
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Standard Therapy ◽  
Ganoderma Lucidum ◽  
Severe Pain ◽  
Dry Weight ◽  
Water Soluble ◽  
Hot Water ◽  
Herpes Zoster Infection

Administration of hot water soluble extracts of Ganoderma lucidum (GI) (36 to 72 g dry weight/day) decreased pain dramatically in two patients with postherpetic neuralgia recalcitrant to standard therapy and two other patients with severe pain due to herpes zoster infection.

scholarly journals Shingles: Extensive Clinical Presentation of Herpes Zoster Infection

2020 ◽  
Vol 22 (2) ◽  
pp. 122-125
Author(s):  
Nazmul Hossain Chowdhury ◽  
Akhil Chandra Biswas ◽  
Md Ashraful Islam ◽  
Farid Uddin Milki ◽  
Saif Rahman Khan
Keyword(s):  
Herpes Zoster ◽  
Immune Function ◽  
Postherpetic Neuralgia ◽  
Vision Loss ◽  
Clinical Presentation ◽  
Signs And Symptoms ◽  
Viral Disease ◽  
Varicella Zoster ◽  
Duration Of Disease ◽  
Antiviral Medications

Shingles, also known as zoster, herpes zoster, or zona, is a viral disease characterized by painful skin rash with blisters.Typically the rash occurs on either side of face in a single stripe. Two to four days before the rash occurs there may be pain or tingling in the area. The rash usually heals within two to four weeks.Ongoing nerve pain may last for months or years,condition called postherpetic neuralgia. In those with poor immune function the rash may occur widely. If the rash involves the eye, vision loss may occur. Shingles is due to a reactivation of varicella zoster virus (VZV) within body. Chickenpox is due to an initial infection with VZV. Once chickenpox has resolved, the virus may remain inactive in nerve cells. Risk factors for reactivation include older age, poor immune function, and having had chickenpox before 18 months of age. Diagnosis is typically based on signs and symptoms. The shingles vaccine decreases the chance of shingles by about half in those between the ages of 50 and 80. It also decreases rates of postherpetic neuralgia. Antiviral medications such as aciclovir can reduce the severity and duration of disease if started within 72 hours of the appearance of the rash. NSAIDs or opioids may be used to help with the acute pain.It is estimated that about a third of people develop shingles at some point in their life. children may also get the disease. The number of new cases per year ranges from 1.2–3.4 per 1,000. Bangladesh J Otorhinolaryngol; October 2016; 22(2): 122-125  

scholarly journals Treatment resistant postherpetic neuralgia - new treatments, better outcome

2020 ◽  
Vol 24 (4) ◽  
Author(s):  
Liliane Godinho ◽  
Margarida Anastcio ◽  
Ana Sofia Pereira ◽  
Maria Conceço Martins ◽  
Ana Valentim
Keyword(s):  
Herpes Zoster ◽  
Postherpetic Neuralgia ◽  
Persistent Pain ◽  
Treatment Resistant ◽  
Herpes Zoster Infection ◽  
Painful Condition ◽  
Infection Management ◽  
New Treatments

Postherpetic neuralgia (PHN) is a chronic and painful condition characterized by persistent pain following resolution of a Herpes zoster infection. Management of PHN can be challenging as this disorder is difficult to treat and many strategies have been described to reduce such pain.

Sign in / Sign up

Export Citation Format

Share Document